Navigation Links
Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

http://www.reportlinker.com/p0660754/Central-Nervous-System-Disorders-Therapeutics-Market-to-2017---Multiple-Sclerosis-Major-Depressive-Disorder-and-Schizophrenia-Accounted-for-Half-the-Market-Value-in-2010.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010", which provides insights into CNS disorder therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major CNS disorder including Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD), bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. The report also provides the share of generics in global CNS disorder therapeutics market as well as in each indication market. The report examines the global CNS disorder treatment usage patterns. In addition, the geographical distribution of CNS disorder and market across the US, the top five countries of Europe and in Japan. The report also includes insights into the CNS disorder R&D product pipeline and explores the competitive landscape including major players in CNS disease market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that took place in CNS disorder therapeutics market.

GBI Research analysis shows that the overall global CNS disorder therapeutics market for the eleven indications that includes Alzheimer's disease, multiple sclerosis, Parkinson's disease, diabetic neuropathy, major depressive disorder (MDD),bipolar disorder, schizophrenia insomnia, epilepsy, attention deficit hyperactivity disorder (ADHD) and migraine. valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 indicating a CAGR of 4.7% The market is expected to witness a fluctuation in a view of patent expiries followed by generic erosion and possible launch of novel molecules. The market is expected to witness a comparatively slow growth at a CAGR of 1.4% between 2010 and 2017 and is estimated to reach $58.6 billion in 2017. Rising geriatric population all over the world, increased life expectancy along with anticipated launch of novel molecules will drive the growth of CNS disease market in future. The market for Alzheimer's disease and multiple sclerosis is expected to witness a significant growth due to expected launch of promising molecules with disease modifying characteristic and novel mechanism of action. Patent expiries of drugs in recent and upcoming years is the only barrier to global CNS disorder therapeutics market however expected launch of novel molecules with disease modifying characteristic and better safety and efficacy will drive the market in forecast period.

Scope

- Data and analysis on the CNS disorder therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the CNS disorder therapeutics market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Share of the generics in global CNS disorder therapeutics market and for the market of each indication that is covered in the report.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global CNS disorder therapeutics market including top companies benchmarking. The key companies studied in this report are Eli Lilly, Pfizer, AstraZeneca, Teva, and Johnson & Johnson.

- Key M&A activities and Licensing Agreements that took place in 2009 and 2010 in the CNS disease market.

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Device a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 8

1.2 List of Figures 12

2 CNS Disorder Therapeutic Market to 2017 - Introduction 15

2.1 GBI Research Report Guidance 15

3 CNS Disorder Therapeutic Market to 2017 - Global Market Overview 16

3.1 Introduction 16

3.2 Revenue 17

3.2.1 Generic Share 18

3.2.2 Annual Cost of Treatment 19

3.3 Top CNS Drug Products 20

3.3.1 Seroquel (IR/XR) (quetiapine fumarate) 20

3.3.2 Zyprexa (olanzapine) 20

3.3.3 Cymbalta (duloxetine Hcl) 21

3.3.4 Copaxone (glatiramer acetate) 21

3.3.5 Lyrica (pregabalin) 22

3.3.6 Abilify (aripiprazole) 22

3.3.7 Avonex (Interferon beta-1a) 23

3.3.8 Rebif (interferon beta-1a) 23

3.3.9 Effexor (venlafaxine) 23

3.3.10 Betaferon /Betaseron (Interferon beta-1b) 24

4 CNS Disorder Therapeutic Market to 2017 - Geographical Landscape 25

4.1 Revenue Analysis by Geography 25

4.2 The US 26

4.2.1 Revenue 26

4.2.2 Annual Cost of Treatment 27

4.3 Top Five Countries of Europe 28

4.3.1 Revenue 28

4.3.2 Annual Cost of Treatment 30

4.4 Japan 31

4.4.1 Revenue 31

4.4.2 Annual Cost of Treatment 32

5 CNS Disorder Therapeutic Market to 2017 - Therapeutic Landscape 33

5.1 Alzheimer's Disease 33

5.1.1 Introduction 33

5.1.2 Revenue 35

5.1.3 Annual Cost of Treatment 39

5.1.4 Treatment Usage Patterns 40

5.2 Drivers and Restraints to Alzheimer's Disease Market 42

5.2.1 Drivers for Alzheimer's disease Market 42

5.2.2 Restraints for Alzheimer's disease Market 43

5.3 Attention Deficit Hyperactivity Disorder (ADHD) 43

5.3.1 Introduction 43

5.3.2 Revenue 45

5.3.3 Annual Cost of Treatment 49

5.3.4 Treatment Usage Patterns 50

5.4 Drivers and Barriers to ADHD Market 52

5.4.1 Drivers for ADHD Market 52

5.4.2 Barriers for ADHD Market 52

5.5 Bipolar Disorder 53

5.5.1 Introduction 53

5.5.2 Revenue 55

5.5.3 Annual Cost of Treatment 58

5.5.4 Treatment Usage Patterns 59

5.6 Drivers and Barriers to Bipolar Disorder Market 61

5.6.1 Drivers for Bipolar Disorder Market 61

5.6.2 Barriers for Bipolar Disorder Market 61

5.7 Diabetic Neuropathy 62

5.7.1 Introduction 62

5.7.2 Revenue 64

5.7.3 Annual Cost of Treatment 67

5.7.4 Treatment Usage Pattern 68

5.8 Drivers and Restraints to Diabetic Neuropathy Market 70

5.8.1 Drivers for Diabetic Neuropathy Market 70

5.8.2 Restraints for the Diabetic Neuropathy Therapeutics Market 70

5.9 Epilepsy 71

5.9.1 Introduction 71

5.9.2 Revenue 72

5.9.3 Annual Cost of Treatment 75

5.9.4 Treatment Usage Patterns 76

5.10 Drivers and Barriers to Epilepsy Market 78

5.10.1 Drivers for Epilepsy Market 78

5.10.2 Barriers to Epilepsy Market 78

5.11 Insomnia 79

5.11.1 Introduction 79

5.11.2 Revenue 81

5.11.3 Annual Cost of Treatment 84

5.11.4 Treatment Usage Patterns 85

5.12 Drivers and Barriers to Insomnia Market 87

5.12.1 Drivers for Insomnia Market 87

5.12.2 Barriers for Insomnia Market 88

5.13 Migraine 88

5.13.1 Introduction 88

5.13.2 Revenue 90

5.13.3 Annual Cost of Treatment 94

5.13.4 Treatment Usage Patterns 95

5.14 Drivers and Barriers for Migraine Market 98

5.14.1 Drivers for Migraine Market 98

5.14.2 Barriers for Migraine Market 99

5.15 Multiple Sclerosis 99

5.15.1 Introduction 99

5.15.2 Revenue 102

5.15.3 Annual Cost of Treatment 106

5.15.4 Treatment Usage Patterns 107

5.16 Drivers and Restraints to Multiple Sclerosis Therapeutics Market 109

5.16.1 Drivers for Multiple Sclerosis Market 109

5.16.2 Restraints for Multiple Sclerosis Market 110

5.17 Parkinson's Disease 110

5.17.1 Introduction 110

5.17.2 Revenue 112

5.17.3 Annual Cost of Treatment 115

5.17.4 Treatment Usage Patterns 116

5.18 Drivers and Restraints to Parkinson's Disease Therapeutics Market 118

5.18.1 Drivers for the Parkinson's disease Therapeutics Market 118

5.18.2 Restraints for the Parkinson's disease Therapeutics Market 118

5.19 Schizophrenia 119

5.19.1 Introduction 119

5.19.2 Revenue 121

5.19.3 Annual Cost of Treatment 124

5.19.4 Treatment Usage Pattern 125

5.20 Drivers and Barriers to Schizophrenia Market 127

5.20.1 Drivers for Schizophrenia Market 127

5.20.2 Barriers for Schizophrenia Market 128

5.21 Major Depressive Disorder (MDD) 128

5.21.1 Introduction 128

5.21.2 Revenue 130

5.21.3 Annual Cost of Treatment 133

5.21.4 Treatment Usage Patterns 134

5.22 Drivers and Barriers to MDD Market 136

5.22.1 Drivers for MDD Market 136

5.22.2 Barriers for MDD Market 136

6 Central Nervous System Disorders Therapeutics Market to 2017 - Product Pipeline Analysis 138

6.1 Introduction 138

6.1.1 Product Pipeline by Indication 138

6.1.2 Product Pipeline by Clinical Stage of Development 139

6.2 Alzheimer's disease 140

6.2.1 Introduction 140

6.3 Attention Deficit Hyperactivity Disorder (ADHD) 150

6.3.1 Introduction 150

6.4 Bipolar Disorder 153

6.4.1 Introduction 153

6.5 Diabetic Neuropathy 155

6.5.1 Introduction 155

6.6 Epilepsy 157

6.6.1 Introduction 157

6.7 Insomnia 161

6.7.1 Introduction 161

6.8 Major Depressive Disorder (MDD) 163

6.8.1 Introduction 163

6.9 Migraine 167

6.9.1 Introduction 167

6.10 Multiple Sclerosis 169

6.10.1 Introduction 169

6.11 Parkinson's Disease 175

6.11.1 Introduction 175

6.12 Schizophrenia 182

6.12.1 Introduction 182

6.13 NDA Filed Molecules 186

6.13.1 Alzheimer's disease 186

6.13.2 Bipolar Disorder 187

6.13.3 Epilepsy 189

6.13.4 Insomnia 191

6.13.5 MDD 193

6.13.6 Migraine 194

6.13.7 Parkinson's disease 195

6.13.8 Multiple sclerosis 195

7 CNS Disorder Therapeutic Market to 2017 - Competitive Landscape 198

7.1 Market Share Analysis 198

7.1.1 Eli Lilly 199

7.1.2 Pfizer 200

7.1.3 AstraZeneca 201

7.1.4 Johnson & Johnson (J&J) 202

7.1.5 Teva 203

8 CNS Disorder Therapeutic Market to 2017 - M&A Landscape 204

8.1 M&A Deals (2010-2011) 204

8.1.1 M&A Deals by Region 204

8.1.2 M&A Deals by Indication 205

8.1.3 M&A Deals by Value 206

8.1.4 Deal Summary of M&A Deals by Value 209

8.2 Licensing Deals 212

8.2.1 Deal Summary 216

8.3 Co-development Deals 218

8.3.1 Deal Summary 220

9 CNS Disorder Therapeutic Market to 2017 - Appendix 223

9.1 Market Definitions 223

9.2 Abbreviations 223

9.3 Research Methodology 224

9.3.1 Coverage 224

9.3.2 Secondary Research 225

9.3.3 Primary Research 225

9.3.4 Therapeutic Landscape 226

9.3.5 Geographical Landscape 229

9.3.6 Pipeline Analysis 229

9.3.7 Competitive Landscape 229

9.3.8 Expert Panel Validation 229

9.4 Contact Us 229

9.5 Disclaimer 229

9.6 Sources 230

1.1 List of Tables

Table 1: CNS Disorder Therapeutic Market, Global, Revenue ($bn), 2002-2010 17

Table 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2010-2017 17

Table 3: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2010 18

Table 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2010-2017 18

Table 5: CNS Disorder Therapeutic Market, The US, Revenue ($m), 2002-2010 25

Table 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast($m), 2010-2017 25

Table 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2010 26

Table 8: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2010-2017 26

Table 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 28

Table 10: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2010-2017 28

Table 11: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 29

Table 12: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 29

Table 13: CNS Disorder Therapeutic Market, Japan, Revenue ($m), 2002-2010 30

Table 14: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2010-2017 30

Table 15: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2010 31

Table 16: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2010-2017 31

Table 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, FDA Approved Cholinesterase Inhibitors, 2010 33

Table 18: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue ($bn), 2002-2010 34

Table 19: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2010-2017 34

Table 20: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2010 36

Table 21: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2010-2017 36

Table 22: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2010 38

Table 23: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2010-2017 38

Table 24: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 39

Table 25: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 40

Table 26: CNS Disorder Therapeutic Market, ADHD, Global Revenue ($m), 2002-2010 45

Table 27: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2010-2017 45

Table 28: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2010 46

Table 29: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2010-2017 46

Table 30: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2010 48

Table 31: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2010-2017 48

Table 32: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2010 49

Table 33: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2010-2017 50

Table 34: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue ($m), 2002-2010 54

Table 35: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2010-2017 54

Table 36: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2010 55

Table 37: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2010-2017 56

Table 38: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2010 57

Table 39: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2010-2017 57

Table 40: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2010 58

Table 41: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2010-2017 59

Table 42: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue ($m), 2002-2010 63

Table 43: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast($m), 2010-2017 63

Table 44: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2010 64

Table 45: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2010-2017 65

Table 46: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2010 66

Table 47: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2010-2017 66

Table 48: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2010 67

Table 49: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2010-2017 68

Table 50: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue ($m), 2002-2010 71

Table 51: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2010-2017 71

Table 52: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2002-2010 72

Table 53: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m), 2010-2017 73

Table 54: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2010 74

Table 55: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2010-2017 74

Table 56: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2010 75

Table 57: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2010-2017 76

Table 58: CNS Disorder Therapeutic Market, Insomnia, Global Revenue ($m), 2002-2010 80

Table 59: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast($m), 2010-2017 80

Table 60: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2010 81

Table 61: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2010-2017 82

Table 62: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2010 83

Table 63: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2010-2017 83

Table 64: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2010 84

Table 65: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2010-2017 85

Table 66: CNS Disorder Therapeutic Market, Migraine, Global Revenue ($m), 2002-2010 89

Table 67: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast($m), 2010-2017 90

Table 68: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2002–2010 91

Table 69: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2010–2017 91

Table 70: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2010 93

Table 71: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2010-2017 93

Table 72: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2010 95

Table 73: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2010-2017 95

Table 74: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue ($m), 2002-2010 102

Table 75: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2010-2017 102

Table 76: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2010 103

Table 77: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2010-2017 104

Table 78: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2010 105

Table 79: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2010-2017 105

Table 80: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2010 106

Table 81: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2010-2017 107

Table 82: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue ($m), 2002-2010 111

Table 83: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue Forecast ($m), 2010-2017 111

Table 84: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2002-2010 112

Table 85: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2010-2017 113

Table 86: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2010 114

Table 87: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2010-2017 114

Table 88: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2010 115

Table 89: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2010-2017 116

Table 90: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue ($m), 2002-2010 120

Table 91: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2010-2017 120

Table 92: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2010 121

Table 93: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2010-2017 122

Table 94: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 123

Table 95: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2010-2017 123

Table 96: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2010 124

Table 97: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2010-2017 125

Table 98: CNS Disorder Therapeutic Market, MDD, Global Revenue ($m), 2002-2010 129

Table 99: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast ($m), 2010-2017 130

Table 100: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2010 130

Table 101: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2010-2017 131

Table 102: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2010 132

Table 103: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2010-2017 132

Table 104: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2002-2010 133

Table 105: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Patterns (Thousand), 2010-2017 134

Table 106: CNS Disorder Therapeutic Market, Alzheimer's Disease, Discovery Product Pipeline, 2011 140

Table 107: CNS Disorder Therapeutic Market, ADHD Product Pipeline, 2011 150

Table 108: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline, 2011 153

Table 109: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline, 2011 155

Table 110: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline, 2011 157

Table 111: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline, 2011 161

Table 112: CNS Disorder Therapeutic Market, MDD, Product Pipeline, 2011 163

Table 113: CNS Disorder Therapeutic Market, Migraine, Product Pipeline, 2011 167

Table 114: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline, 2011 169

Table 115: CNS Disorder Therapeutic Market, Parkinson's Disease, Product Pipeline, 2011 175

Table 116: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline, 2011 182

Table 117: CNS Disorder Therapeutic Market, Global, M&A Deals ($m), 2010-2011 206

Table 118: CNS Disorder Therapeutic Market, Global, Announced M&A Deals ($m), 2010-2011 207

Table 119: CNS Disorder Therapeutic Market, Global, Licensing Deals ($m), 2010-2011 212

Table 120: CNS Disorder Therapeutic Market, Co-developments, 2010-2011 218

1.2 List of Figures

Figure 1: CNS Disorder Therapeutic Market, Global, Revenue Share by Indication (%), 2010 16

Figure 2: CNS Disorder Therapeutic Market, Global, Revenue Forecast ($bn), 2002-2017 17

Figure 3: CNS Disorder Therapeutic Market, Global, Generic Share (%), 2010 and 2017 18

Figure 4: CNS Disorder Therapeutic Market, Global, Annual Cost of Treatment ($), 2002-2017 19

Figure 5: CNS Disorder Therapeutic Market, Revenue by Geography (%),2010 25

Figure 6: CNS Disorder Therapeutic Market, The US, Revenue Forecast ($m), 2002-2017 26

Figure 7: CNS Disorder Therapeutic Market, The US, Annual Cost of Treatment ($), 2002-2017 27

Figure 8: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Revenue Forecast ($m), 2002-2017 28

Figure 9: CNS Disorder Therapeutic Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 30

Figure 10: CNS Disorder Therapeutic Market, Japan, Revenue Forecast ($m), 2002-2017 31

Figure 11: CNS Disorder Therapeutic Market, Japan, Annual Cost of Treatment ($), 2002-2017 32

Figure 12: CNS Disorder Therapeutic Market, Alzheimer's Disease Treatment Algorithm 34

Figure 13: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Revenue Forecast ($bn), 2002-2017 35

Figure 14: CNS Disorder Therapeutics Market, Alzheimer's Disease, Revenue by Country ($m), 2002-2017 36

Figure 15: CNS Disorder Therapeutic Market, Alzheimer's Disease, Generic Share in Alzheimer's Disease Market, 2010 and 2017 38

Figure 16: CNS Disorder Therapeutic Market, Alzheimer's Disease, Annual Cost of Treatment ($), 2002-2017 39

Figure 17: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 40

Figure 18: CNS Disorder Therapeutic Market, Alzheimer's Disease, Global Market Drivers and Restraints, 2010-2017 42

Figure 19: CNS Disorder Therapeutic Market, ADHD Treatment Algorithm 44

Figure 20: CNS Disorder Therapeutic Market, ADHD, Global Revenue Forecast ($m), 2002-2017 46

Figure 21: CNS Disorder Therapeutic Market, ADHD, Revenue by Country ($m), 2002-2017 47

Figure 22: CNS Disorder Therapeutic Market, ADHD, Generic Share in ADHD Market, 2010 and 2017 48

Figure 23: CNS Disorder Therapeutic Market, ADHD, Annual Cost of Treatment ($), 2002-2017 49

Figure 24: CNS Disorder Therapeutic Market, ADHD, Global Treatment Usage Patterns (Thousand), 2002-2017 50

Figure 25: CNS Disorder Therapeutic Market, ADHD, Global Market Drivers and Barriers, 2010-2017 52

Figure 26: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 54

Figure 27: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Revenue Forecast ($m), 2002-2017 55

Figure 28: CNS Disorder Therapeutic Market, Bipolar Disorder, Revenue by Country ($m), 2002-2017 56

Figure 29: CNS Disorder Therapeutic Market, Bipolar Disorder, Generic Share in Bipolar Disorder Market, 2010 and 2017 57

Figure 30: CNS Disorder Therapeutic Market, Bipolar Disorder, Annual Cost of Treatment ($), 2002-2017 58

Figure 31: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Treatment Usage Patterns (Thousand), 2002-2017 59

Figure 32: CNS Disorder Therapeutic Market, Bipolar Disorder, Global Market Drivers and Barriers, 2010-2017 61

Figure 33: CNS Disorder Therapeutic Market, Bipolar Disorder, Treatment Algorithm 63

Figure 34: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Revenue Forecast ($m), 2002-2017 64

Figure 35: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Revenue by Country ($m), 2002-2017 65

Figure 36: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Generic Share in Diabetic Neuropathy Market ($m), 2010 and 2017 66

Figure 37: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Annual Cost of Treatment ($), 2002-2017 67

Figure 38: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Treatment Usage Pattern (Thousand), 2002-2017 68

Figure 39: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Global Market Drivers and Restraints, 2010-2017 70

Figure 40: CNS Disorder Therapeutic Market, Epilepsy, Treatment Algorithm 71

Figure 41: CNS Disorder Therapeutic Market, Epilepsy, Global Revenue Forecast ($m), 2002-2017 72

Figure 42: CNS Disorder Therapeutic Market, Epilepsy, Revenue by Country ($m),2002-2017 73

Figure 43: CNS Disorder Therapeutic Market, Epilepsy, Generic Share in Epilepsy Market, 2010 and 2017 74

Figure 44: CNS Disorder Therapeutic Market, Epilepsy, Annual Cost of Treatment ($), 2002-2017 75

Figure 45: CNS Disorder Therapeutic Market, Epilepsy, Global Treatment Usage Patterns (Thousand), 2002-2017 76

Figure 46: CNS Disorder Therapeutic Market, Epilepsy, Global Market Drivers and Barriers, 2010-2017 78

Figure 47: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 80

Figure 48: CNS Disorder Therapeutic Market, Insomnia, Global Revenue Forecast ($m), 2002-2017 81

Figure 49: CNS Disorder Therapeutic Market, Insomnia, Revenue by Country ($m), 2002-2017 82

Figure 50: CNS Disorder Therapeutic Market, Insomnia, Generic Share in Insomnia Market, 2010 and 2017 83

Figure 51: CNS Disorder Therapeutic Market, Insomnia, Annual Cost of Treatment ($), 2002-2017 84

Figure 52: CNS Disorder Therapeutic Market, Insomnia, Global Treatment Usage Patterns (Thousand), 2002-2017 85

Figure 53: CNS Disorder Therapeutic Market, Insomnia, Global Market Drivers and Barriers, 2010-2017 87

Figure 54: CNS Disorder Therapeutic Market, Migraine, Treatment Algorithm 89

Figure 55: CNS Disorder Therapeutic Market, Migraine, Global Revenue Forecast ($m), 2002-2017 90

Figure 56: CNS Disorder Therapeutic Market, Migraine, Revenue by Country ($m), 2002-2017 91

Figure 57: CNS Disorder Therapeutic Market, Migraine, Generic Share in Migraine Market, 2010 and 2017 93

Figure 58: CNS Disorder Therapeutic Market, Migraine, Annual Cost of Treatment ($), 2002-2017 94

Figure 59: CNS Disorder Therapeutic Market, Migraine, Global Treatment Usage Patterns (Thousand), 2002-2017 95

Figure 60: CNS Disorder Therapeutic Market, Migraine, Global Market Drivers and Barriers, 2010-2017 98

Figure 61: CNS Disorder Therapeutic Market, Multiple Sclerosis (RRMS), Treatment Algorithm 101

Figure 62: CNS Disorder Therapeutic Market, Multiple Sclerosis (PRMS), Treatment Algorithm 102

Figure 63: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Revenue Forecast ($m), 2002-217 103

Figure 64: CNS Disorder Therapeutic Market, Multiple Sclerosis, Revenue by Country ($m), 2002-2017 104

Figure 65: CNS Disorder Therapeutic Market, Multiple Sclerosis, Generic Share in Multiple Sclerosis Market, 2010 and 2017 105

Figure 66: CNS Disorder Therapeutic Market, Multiple Sclerosis, Annual Cost of Treatment ($), 2002-2017 106

Figure 67: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Treatment Usage Pattern (Thousand), 2002-2017 107

Figure 68: CNS Disorder Therapeutic Market, Multiple Sclerosis, Global Market Drivers and Restraints, 2010-2017 109

Figure 69: CNS Disorder Therapeutic Market, Parkinson's Disease, Treatment Algorithm 111

Figure 70: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Revenue Forecast($m), 2002-2017 112

Figure 71: CNS Disorder Therapeutic Market, Parkinson's Disease, Revenue by Country ($m), 2002-2017 113

Figure 72: CNS Disorder Therapeutic Market, Parkinson's Disease, Generic Share in Parkinson's Disease Market ($m), 2010 and 2017 114

Figure 73: CNS Disorder Therapeutic Market, Parkinson's Disease, Annual Cost of Treatment ($), 2002-2017 115

Figure 74: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Treatment Usage Pattern (Thousand), 2002-2017 116

Figure 75: CNS Disorder Therapeutic Market, Parkinson's Disease, Global Market Drivers and Restraints, 2010-2017 118

Figure 76: CNS Disorder Therapeutic Market, Schizophrenia, Treatment Algorithm 120

Figure 77: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue Forecast ($m), 2002-2017 121

Figure 78: CNS Disorder Therapeutic Market, Schizophrenia, Global Revenue by Country ($m), 2002-2017 122

Figure 79: CNS Disorder Therapeutic Market, Schizophrenia, Generic Share in Schizophrenia Market, 2010 and 2017 123

Figure 80: CNS Disorder Therapeutic Market, Schizophrenia, Annual Cost of Treatment ($), 2002-2010 124

Figure 81: CNS Disorder Therapeutic Market, Schizophrenia, Global Treatment Usage Pattern (Thousand), 2002-2017 125

Figure 82: CNS Disorder Therapeutic Market, Schizophrenia, Global Market Drivers and Barriers, 2010-2017 127

Figure 83: CNS Disorder Therapeutic Market, Insomnia, Treatment Algorithm 129

Figure 84: CNS Disorder Therapeutic Market, MDD, Global Revenue Forecast($m), 2002-2017 130

Figure 85: CNS Disorder Therapeutic Market, MDD, Revenue by Country ($m), 2002-2017 131

Figure 86: CNS Disorder Therapeutic Market, MDD, Generic Share in MDD Market, 2010 and 2017 132

Figure 87: CNS Disorder Therapeutic Market, MDD, Annual Cost of Treatment ($), 2002-2017 133

Figure 88: CNS Disorder Therapeutic Market, MDD, Global Treatment Usage Pattern (Thousand), 2002-2017 134

Figure 89: CNS Disorder Therapeutic Market, MDD, Global Market Drivers and Barriers, 2010-2017 136

Figure 90: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Indication (%),2011 138

Figure 91: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline by Clinical Stage of Development (%),2011 139

Figure 92: CNS Disorder Therapeutic Market, Alzheimer's Disease, Product Pipeline (%),2011 140

Figure 93: CNS Disorder Therapeutic Market, ADHD, Product Pipeline (%), 2011 150

Figure 94: CNS Disorder Therapeutic Market, Bipolar Disorder, Product Pipeline (%),2011 153

Figure 95: CNS Disorder Therapeutic Market, Diabetic Neuropathy, Product Pipeline (%),2011 155

Figure 96: CNS Disorder Therapeutic Market, Epilepsy, Product Pipeline (%),2011 157

Figure 97: CNS Disorder Therapeutic Market, Insomnia, Product Pipeline (%), 2011 161

Figure 98: CNS Disorder Therapeutic Market, MDD, Product Pipeline (%),2011 163

Figure 99: CNS Disorder Therapeutic Market, Migraine, Product Pipeline (%), 2011 167

Figure 100: CNS Disorder Therapeutic Market, Multiple Sclerosis, Product Pipeline (%), 2011 169

Figure 101: CNS Disorder Therapeutic Market, Parkinson's Disease, Product Pipeline (%), 2011 175

Figure 102: CNS Disorder Therapeutic Market, Schizophrenia, Product Pipeline (%), 2011 182

Figure 103: CNS Disorder Therapeutic Market, Global Top Companies Share (%), 2010 198

Figure 104: CNS Disorder Therapeutic Market, SWOT Analysis of Eli Lilly, 2010 199

Figure 105: CNS Disorder Therapeutic Market, SWOT Analysis of Pfizer, 2010 200

Figure 106: CNS Disorder Therapeutic Market, SWOT Analysis of AstraZeneca, 2010 201

Figure 107: CNS Disorder Therapeutic Market, SWOT Analysis of Johnson & Johnson, 2010 202

Figure 108: CNS Disorder Therapeutic Market, SWOT Analysis of Teva 203

Figure 109: CNS Disorder Therapeutic Market, Global M&A Deals by Region, 2010-2011 204

Figure 110: CNS Disorder Therapeutic Market, Global M&A Deals by Indication, 2010-2011 205

Figure 111: CNS Disorder Therapeutic Market, Global, M&A Deals by Value ($m), 2010-2011 206

Figure 112: CNS Disorder Therapeutic Market, Licensing Deals, by Indication, 2010-2011 212

Figure 113: CNS Disorder Therapeutic Market, Co-developments by Indication, 2010-2011 218

Figure 114: GBI Research Market Forecasting Model 228

Companies Mentioned

Eli Lilly

Pfizer

AstraZeneca

Johnson & Johnson (J&J)

Teva

To order this report:

Pathology Industry: Central Nervous System Disorders Therapeutics Market to 2017 - Multiple Sclerosis, Major Depressive Disorder and Schizophrenia Accounted for Half the Market Value in 2010

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Bioness Inc. Receives FDA Clearance and CE Mark for Its NESS H200 Wireless System for Hand Paralysis as a Result of Stroke and Other Central Nervous System Disorders
2. South and Central America Cardiovascular Devices Market Outlook to 2017
3. Carolinas HealthCare System (CHS) Contributes to First Childrens Burn Hospital in Central America
4. Pharmaceutical Contract Manufacturing and API Sourcing in Central Europe and the Balkan States 2011
5. United Seating & Mobility Reaches Agreement to Acquire Central Kentucky Mobility
6. Reportlinker Adds South and Central America Dental Devices Market Outlook to 2017
7. Reportlinker Adds South and Central America Drug Delivery Devices Market Outlook to 2017
8. Reportlinker Adds Drug Delivery Devices Market Outlook in United Kingdom to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
9. Reportlinker Adds Drug Delivery Devices Market Outlook in Brazil to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
10. Reportlinker Adds Drug Delivery Devices Market Outlook in Russian Federation to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
11. Reportlinker Adds Drug Delivery Devices Market Outlook in China to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... June 23, 2016 Bracket , a leading ... next generation clinical outcomes platform, Bracket eCOA (SM) 6.0, ... June 26 – 30, 2016 in Philadelphia ... Clinical Outcome Assessment product of its kind to fully integrate ... Bracket eCOA 6.0 is a flexible platform for electronic ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):